UPDATE – Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020

Rhea-AI Summary

Liquidia Technologies (Nasdaq:LQDA) will report its third quarter 2020 financial results on November 6, 2020. A webcast and conference call to discuss these results is scheduled for November 9, 2020, at 8:00 a.m. ET. The company specializes in developing novel biopharmaceuticals using its proprietary PRINT® technology, focusing on two main product candidates: LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain. The event will allow investors to gain insights into the company's performance and future outlook.

News Market Reaction – LQDA

-27.71%

-27.71% Session move

In the trading session that priced this news, LQDA declined 27.71%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to Host Webcast and Conference Call November 9, 2020 at 8:00a.m. ET

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT^® technology, today announced that third quarter 2020 financial results will be reported on Friday, November 6, 2020. The company will host a webcast and conference call on Monday, November 9, 2020 at 8:00 a.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 7617005. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT^® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com

 

FAQ

When will Liquidia Technologies report its third quarter 2020 financial results?

Liquidia Technologies will report its third quarter 2020 financial results on November 6, 2020.

What time is Liquidia's conference call on November 9, 2020?

The conference call will take place at 8:00 a.m. ET on November 9, 2020.

How can I access Liquidia Technologies' conference call?

You can access the conference call by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 7617005.

What is Liquidia Technologies' focus in the biopharmaceutical industry?

Liquidia Technologies focuses on developing novel products using its PRINT^® technology for various therapies, particularly for pulmonary arterial hypertension and post-operative pain.